You are here

  • Home
  • Archive
  • Volume 11, Issue 11
  • Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high …

Citation Tools

Article menu
Immunotherapy biomarkers
Original research
Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
He J, Kalinava N, Doshi P, et al
Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB
Journal for ImmunoTherapy of Cancer 2023;11:e007339. doi: 10.1136/jitc-2023-007339